7:40AM POZEN reports EPS in-line, beats on revs; co is re-evaluating financial outlook for the year (POZN) 6.66 : Reports Q1 (Mar) loss of $0.28 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.28); revenues fell 71.1% year/year to $1.3 mln vs the $1.2 mln consensus. In light of the recent discussions with the FDA regarding the NDA for PA32540, they are re-evaluating their financial outlook for the year, which they will update when they complete their assessment.
Market Data 
Markets 
AI
